ECTRIMS 2021: Ocrelizumab Maintains Near Complete Suppression of Focal MRI Disease Activity of RRMS
Advantages gained by patients randomized initially to ocrelizumab persisted.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.